Skip To Main Content
Rupert Bartsch on Muck Rack

Rupert Bartsch

As seen in: Nature, MDPI, Medscape, The Lancet, ONCOLOGY journal, OncLive, Cancer Treatment Reviews
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work. Claim your profile

Get in touch with Rupert

Contact Rupert, search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack

Actions

Share this page

Is this you?

As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile

Articles

109 Extended Adjuvant Neratinib in HER2+/HR+ Early Breast Cancer in Clinical Routine: Final Results from the Multi-national, Prospective, Observational Study ELEANOR

|
By Diana Lüftner, Rupert Bartsch, Urs Breitenstein
| ONCOLOGY journal Verified
Background Neratinib is an oral, irreversible pan-HER tyrosine kinase inhibitor approved in Europe as extended adjuvant treatment for adult patients with HER2-positive/hormone receptor–positive early breast cancer who completed adjuvant trastuzumab-based therapy less than 1 year ago. In the phase 3 ExteNET study, neratinib significantly improved 2-year invasive disease-free survival (iDFS) (Δ4.5%, HR,0.49; 95% CI, 0.30-0.78) with an iDFS rate of 95.3% for neratinib.
Open in Who Shared Issue with article?

Comparison of T-DXd-associated pulmonary toxicity in real-world settings and clinical trials

|
By Rupert Bartsch, Christian F. Singer, Maximilian Marhold, Maximilian Hochmair, Kathrin Strasser-Weippl, Simon Udovica, Clemens Leitgeb, Christian Peters-Engl, Verena Sagaster, Muna Ferner, Wolfgang Hilbe
| Nature Verified
Abstract Interstitial lung disease (ILD) is a common and potentially life-threatening adverse event associated with trastuzumab deruxtecan (T-DXd). In the pivotal T-DXd clinical trials, 10–15% of patients developed ILD, with stringent mitigation strategies aimed at the early detection of low-grade cases. Real-world data are urgently needed to assess ILD incidence and outcomes outside controlled trial settings.
Open in Who Shared Issue with article?

Long-term prognostic value of ctDNA in early breast cancer: insights from the neoadjuvant ABCSG-34 Trial

|
By Daniel Egle, Dominik Hlauschek, Simon Peter Gampenrieder, Gabriel Rinnerthaler, Christian F. Singer, Georg Pfeiler, Rupert Bartsch, Gregor Huber, Angelika Pichler, Edgar Petru, Zsuzsanna Bago-Horvath, Christian Fesl, Qing Zhou, Sabrina Hammer, Nadia Dandachi, Martin Filipits, Michael Gnant, Ellen Heitzer, Marija Balic, Anna-Sophia Kermanidis, Ricarda Graf
| Nature Verified
Abstract Circulating tumor DNA (ctDNA) is a promising biomarker in early breast cancer for assessing treatment response, minimal residual disease (MRD), and recurrence risk. In the ABCSG-34 phase II trial, we previously reported that persistent ctDNA during neoadjuvant therapy (NAT) was associated with higher residual cancer burden and lower rates of pathological complete response. Here, we present long-term follow-up data evaluating the prognostic relevance of ctDNA dynamics.
Open in Who Shared Issue with article?
See all 10 licensed articles (12 Total)